Physician profile
Robert V Dimeglio
NPI 1619929973
$2,003.79
in general payments reported to CMS, 2019-2025
36 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $86.73 · 2021: $263 · 2022: $409 · 2023: $119 · 2024: $278 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.21 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $185.25 | 2020-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $185.17 | 2023-2025 | Gemtesa, Orgovyx |
| Medtronic, INC. | $166.30 | 2024-2025 | Interstim, Altaviva |
| Bayer Healthcare Pharmaceuticals INC. | $125.72 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $124.67 | 2022 | |
| Boston Scientific Corporation | $122.00 | 2021 | |
| Procept Biorobotics Corporation | $119.74 | 2019 | |
| Urovant Sciences INC | $116.47 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $111.84 | 2019-2025 | Adstiladrin |
| Janssen Biotech, INC. | $93.31 | 2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $58.62 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $50.13 | 2022-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Urogen Pharma, INC. | $43.55 | 2025 | |
| Stryker Corporation | $37.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $31.35 | 2024-2025 | Azmiro |
| Tolmar, INC. | $30.48 | 2025 | Jatenzo, Eligard |
| Abbvie INC. | $25.89 | 2024 | |
| Endo USA, INC. | $24.74 | 2025 | Xiaflex |
| Myriad Genetic Laboratories, INC. | $24.36 | 2025 | Prolaris |
| Sun Pharmaceutical Industries INC. | $24.05 | 2024 | |
| Rochester Medical Corporation | $21.68 | 2021 | |
| Abc Home Medical Supply, INC. | $21.68 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.94 | 2025 | |
| Endo Pharmaceuticals INC. | $20.54 | 2022 | |
| Acerus Pharmaceuticals Corporation | $19.48 | 2021 | |
| Convatec INC. | $19.43 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $17.35 | 2022 | |
| Progenics Pharmaceuticals, INC. | $17.14 | 2024 | |
| Teleflex LLC | $16.95 | 2023 | Urolift |
| Immunitybio, INC. | $16.78 | 2025 | |
| Agiliti Surgical, INC. | $15.36 | 2025 | Sonablate Hifu, Olympus Soltive Tfl Laser, Quanta System Fiber Dust Tfl Laser |
| Travere Therapeutics, INC. | $15.26 | 2019-2021 | |
| Coloplast Corp | $15.12 | 2025 | |
| Myovant Sciences INC. | $14.98 | 2022 | |
| Valencia Technologies Corporation | $14.63 | 2025 | Ecoin Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dimeglio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.